继续使用相同的编程死亡-1 抑制剂疗法以超越进展是晚期胃癌的新选择
Jiasong Li1,2, Fang Ding3, Shasha Zhang1
1Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, P.R. China.
BMC cancer
|October 18, 2024
概括
在晚期胃癌患者的进展后继续使用相同的编程死亡-1 (PD-1) 抑制剂治疗方案,显著改善了生存结果. 这种方法为免疫治疗超出进展 (IBP) 提供了临床益处.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道癌症 胃肠道癌症
背景情况:
- 胃癌是全球癌症相关死亡的主要原因,往往预后不佳.
- 免疫检查点抑制剂 (ICI),包括编程死亡-1 (PD-1) 抑制剂,改善了生存率,但耐药性仍然是一个挑战.
- 研究超出进展 (IBP) 的免疫治疗策略对于管理晚期胃癌至关重要.
研究的目的:
- 为了评估继续使用相同的编程死亡-1 (PD-1) 抑制剂治疗方案与在先前免疫治疗中进展的晚期胃癌患者中切换到不同的治疗方案的有效性.
- 为了比较这些两种超出进展 (IBP) 的免疫治疗策略之间的临床结果,包括无进展生存率和整体生存率.
主要方法:
- 接受至少两种免疫疗法的晚期胃癌患者被分为两组:相同的PD-1抑制剂疗法 (相同的疗法组) 和不同的PD-1抑制剂疗法 (不同的疗法组) 进行超出进展 (IBP) 的免疫疗法.
- 进行了统计分析,以比较两组患者的特征和生存结果.
主要成果:
- 同一个PD-1抑制剂治疗方案组与不同的治疗方案组相比,表现出更高的疾病控制率 (51.8%对29.2%).
- 继续使用相同的PD-1抑制剂疗法显著延长了无进展生存2 (PFS2) (162 vs. 75天) 和整体生存 (OS) (312 vs. 166天).
- 多变量分析证实,与不同疗法组相比,同一疗法组独立地与改善的PFS2 (HR=0.467) 和OS (HR=0.508) 相关.
结论:
- 在免疫疗法中继续使用相同的编程死亡-1 (PD-1) 抑制剂疗法超出进展 (IBP),在晚期胃癌中显示出显著的临床益处.
- 这一策略代表了对初始免疫疗法进展的患者有前途的治疗方法,从而改善了生存结果.
- 进一步的研究可能会巩固维持一致的PD-1抑制剂治疗在克服治疗耐药性的作用.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.3K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74